Peter Powchik - Regeneron Pharmaceuticals Senior Vice President - Clinical Development
REGN Stock | USD 966.30 2.75 0.29% |
President
Dr. Peter Powchik, M.D., is Senior Vice President Clinical Development of the Company. Dr. Powchik was employed at several pharmaceutical companies, serving as Senior Vice President and Chief Medical Officer of Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporationrationration, most recently as Vice President, US Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his M.D. from New York University School of Medicine. since 2006.
Age | 59 |
Tenure | 18 years |
Address | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 |
Phone | 914 847 7000 |
Web | https://www.regeneron.com |
Regeneron Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1626 %, meaning that it created $0.1626 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.14. Also, Return On Assets is likely to grow to 0.13. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 28th of March 2024, Fixed Asset Turnover is likely to grow to 3.32, while Other Current Assets are likely to drop about 203.9 M.Similar Executives
Found 13 records | PRESIDENT Age | ||
Eilon Asculai | Mediwound | N/A | |
Jacob Thaysen | Agilent Technologies | 49 | |
Bruce CFA | Equillium | 58 | |
Bruce Steel | Equillium | 50 | |
Robert McMahon | Agilent Technologies | 55 | |
Henrik AncherJensen | Agilent Technologies | 59 | |
Patrick Kaltenbach | Agilent Technologies | 53 | |
Mark Doak | Agilent Technologies | 63 | |
Dominique Grau | Agilent Technologies | 65 | |
Rodney Gonsalves | Agilent Technologies | 58 | |
Alicia Rodriguez | Agilent Technologies | N/A | |
Samraat Raha | Agilent Technologies | 51 | |
Michael Tang | Agilent Technologies | 50 |
Management Performance
Return On Equity | 0.16 | ||||
Return On Asset | 0.0849 |
Regeneron Pharmaceuticals Leadership Team
Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Baker, Independent Director | ||
Joseph Goldstein, Independent Director | ||
Anthony Coles, Independent Director | ||
Patrice Gilooly, Senior Operations | ||
Christopher CPA, Head Finance | ||
George Sing, Independent Director | ||
Gerald Underwood, Senior Operations | ||
Peter Powchik, Senior Vice President - Clinical Development | ||
Jay Markowitz, Senior Vice President - Portfolio Management | ||
Robert Terifay, Sr. VP of Commercial | ||
Robert Landry, CFO and Sr. VP of Fin. | ||
Michael Brown, Independent Director | ||
Ryan Crowe, Senior Analysis | ||
Christine Poon, Independent Director | ||
Neil Stahl, Executive VP of RandD | ||
Marion McCourt, Senior Vice President and Head of Commercial | ||
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director | ||
Andrew Murphy, Executive Research | ||
Huda Zoghbi, Director | ||
Bonnie Bassler, Director | ||
Joseph LaRosa, Senior Vice President General Counsel, Secretary | ||
Bob McCowan, Senior Officer | ||
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply | ||
Leonard Schleifer, President CEO, Director | ||
Alfred Gilman, Independent Director | ||
Roy Vagelos, Chairman of the Board | ||
Michael Aberman, Vice President - Strategy | ||
Manisha Narasimhan, IR Contact | ||
Douglas McCorkle, Vice President Controller, Assistant Treasurer | ||
Marc TessierLavigne, Independent Director | ||
Christopher Fenimore, Vice President Controller | ||
Arthur Ryan, Independent Director |
Regeneron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.16 | ||||
Return On Asset | 0.0849 | ||||
Profit Margin | 0.30 % | ||||
Operating Margin | 0.29 % | ||||
Current Valuation | 97.62 B | ||||
Shares Outstanding | 107.94 M | ||||
Shares Owned By Insiders | 2.58 % | ||||
Shares Owned By Institutions | 89.18 % | ||||
Number Of Shares Shorted | 1.39 M | ||||
Price To Earning | 15.51 X |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.78 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.